Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

VRTX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

VRTX

AI Research Report

Powered by Claude

Ready to analyze VRTX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
GILD
Gilead Sciences
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 1991-07-24

Analyst Consensus

Buy
Based on 40 analysts
Period: 2026-04-01
33 Buy (83%)6 Hold (15%)1 Sell (3%)
Rating Distribution
Strong Buy
13
Buy
20
Hold
6
Sell
0
Strong Sell
1
Trend
2026-04
33/6/1
2026-03
31/7/1
2026-02
30/8/1
2026-01
26/12/1
  • Yahoo·3d ago

    Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley

    Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $612 from $596 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Sm

  • Yahoo·3d ago

    Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know

    Vertex Pharmaceuticals (VRTX) reached $436.16 at the closing of the latest trading day, reflecting a -2.38% change compared to its last close.

  • Yahoo·4d ago

    Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative?

    Earlier this week, Halozyme Therapeutics’ subsidiary Halozyme Hypercon announced a global exclusive collaboration and license agreement granting Vertex Pharmaceuticals access to its Hypercon technology for up to three drug targets, in return for a US$15 million upfront payment plus potential milestone and royalty streams. This deal highlights growing pharmaceutical interest in Halozyme’s drug‑delivery platforms, extending their use into hyperconcentrated, lower‑volume formulations that can...

  • Yahoo·4d ago

    How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

  • Benzinga·4d ago

    Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $612

    Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $596 to $612.

  • Yahoo·4d ago

    What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

    Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit growth in earnings.

  • Yahoo·5d ago

    Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use

    Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic fibrosis drugs ALYFTREK and TRIKAFTA, significantly widening the eligible treatment population in the U.S. See our latest analysis for Vertex Pharmaceuticals. The FDA label expansions arrive after a softer patch in the share price, with a 30 day share price return of a 3.68% decline and a 1 year total shareholder return of a 7.96% decline. However, the 3 year and 5 year total...

  • SeekingAlpha·5d ago

    Undercovered Dozen: CVR Energy, Greystone Housing, Conagra Brands, And More

    Discover Seeking Alpha’s Undercovered Dozen: 12 lesser-known stocks with limited analyst coverage and fresh investment ideas from recent articles.

  • View all news →

Recent insider activity

View all →
  • 4FORM 4
    11d ago
  • 4FORM 4
    14d ago
  • 4FORM 4
    28d ago
  • 4FORM 4
    Mar 13
  • 4FORM 4
    Mar 6
📅 Earnings in 20d (May 4)
NASDAQ NMS - GLOBAL MARKETAfter-hours
Vertex Pharmaceuticals Inc
Biotechnology
$440.61
$0.56 (+0.13%)
After-hrs · vs prev close $440.05
Open
$436.64
Prev close
$440.05
Day range
$435.28 – $443.61
52W range
$362.50 – $510.77
Mkt cap
$111.79B
P/E
28.2
EPS
$15.33
Beta
0.35

Factor Grades

View details →
B-
Overall score: 65/100
C
Valuation
B-
Growth
A
Profitability
D+
Momentum
A
Financial Health

Fundamentals

Valuation
Market Cap
$111.79B
P/E (TTM)
28.18S&P avg ~22
P/S (TTM)
9.28S&P avg ~2.8
P/B
6.16S&P avg ~4.5
P/FCF
34.88S&P avg ~26
EPS (TTM)
$15.33
Book/sh
$73.49
Cash/sh
$26.02
Profitability
Gross Margin
86.24%
avg ~45%
Operating Margin
34.77%avg ~15%
Net Margin
32.94%avg ~12%
ROE
22.70%avg ~18%
ROA
16.23%avg ~7%
ROI
22.63%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
8.90%
Rev Growth 5Y
14.10%
EPS Growth YoY
—
EPS Growth 5Y
8.28%
Current Ratio
—
Quick Ratio
2.24
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.35
52W High
$510.77
52W Low
$362.50
Avg Vol (10D)
1.23M
Avg Vol (3M)
1.43M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (40)
Price Performance
5D+1.90%
MTD-1.45%
3M-6.31%
6M+9.22%
YTD-2.94%
1Y-7.45%